Moffitt Cancer Center Researchers Say One Specific MicroRNA Promotes Tumor Growth and Cancer Spread

The study was published in an online issue of Oncogene in January.

MiR-155, which plays an important role in various physiological and pathological processes, is considered an indicator of poor prognosis for breast cancer patients when it is overexpressed. Controlling miR-155 expression could inhibit malignant growth, said the researchers.

“Our study shows that miR-155 is a driver of new blood vessel growth in tumors,” said study lead author Jin Q. Cheng, M.D., Ph.D., senior member of the Cancer Biology and Evolution Program at Moffitt. “It also plays a critical role in metastasis, especially in triple-negative breast cancer. This makes miR-155 both a prognostic marker and a potential therapeutic drug target.”

According to the researchers, several studies show that miR-155 is frequently increased in various human malignancies, including breast, lung, pancreatic and colon cancers. It also regulates a number of cell processes, including growth, survival, migration and invasion. Their study demonstrates that miR-155 promotes new blood vessel growth in breast cancer by targeting a natural tumor suppressor called VHL, part of an important cancer pathway for a cascade of events.
“Further studies could provide insight into the role of miR-155 in inflammation that leads to tumor progression,” noted the researchers, who found elevated miR-155 in triple-negative breast cancer, a form of breast cancer that does not express the genes for estrogen, progesterone and human epidermal growth factor receptors.

“Our findings are important for a number of reasons,” Cheng said. “We have shown that miR-155 targets and downregulates the tumor suppressor VHL and that miR-155 contributes to tumor growth and spread. This makes miR-155 a critical therapeutic target in breast cancer.”

The study was funded by federal grants CA14343, CA15308 and CA137041.
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Since 1999, Moffitt has been listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. With more than 4,200 employees, Moffitt has an economic impact on the state of nearly $2 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, twitter and YouTube.

Media release by Florida Science Communications